Quantity of suitable people: CDEC discussed the uncertainty in the volume of patients with reasonably extreme to significant hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical specialists consulted by CADTH indicated that some patients who will be labeled as possessing mild or average condition might have a severe bleeding https://hemgenix48481.blogpayz.com/36103040/detailed-notes-on-hemgenix